Catalyzed by Embargo Watch, AAS does away with “freely available but embargoed”

Scientific societies must know that tomorrow will mark this week marked* Embargo Watch’s one-year anniversary. How else to explain the mad rush to join our honor roll?

OK, that’s a bit overstated, but forgive my feeling giddy. Here’s why:

Oops! Neurology posts new issue early, lifts embargo

At 9:58 a.m. Eastern Saturday, the American Academy of Neurology — which publishes the journal Neurology — sent out a mea culpa:

Update on Aeron Haworth and Ed Yong: An apology, accepted

As most Embargo Watch readers will probably know, a post describing a tussle between blogger Ed Yong and press information officer (PIO) Aeron Haworth has garnered a lot of attention this week.

Because the comment thread on that post has become a bit, well, umanageable, and is also constrained by a design problem that is making old comments appear to have been in response to new ones, I wanted to call readers’ attention to two comments from the protagonists.

Yong posted this morning:

Cochrane Library lifts embargo on zinc for colds study early after a break

The world is learning the latest evidence on whether zinc can treat the common cold about 90 minutes early today: In response to an embargo break, the Cochrane Library has lifted an embargo. From an email that went out today at 5:37 p.m. Eastern, an hour and 24 minutes before the scheduled embargo time:

How to demonstrate you’re not about transparency — and piss off reporters — as a PIO

Ed Yong, courtesy Ed Yong

Ed Yong just wanted to look at the data.

This past weekend, he found an intriguing embargoed press release about mummy toes and prosthetics, and realized that the “study” to which the release referred was actually just a Perspective in The Lancet. When he emailed the press officer who’d written the release, he learned that the actual data weren’t yet published, but that the Perspective was “peer reviewed using the data.”

Readers of this blog are probably familiar with Yong, science blogger extraordinaire. He writes the extremely popular — and award-winning, for good reason — Not Exactly Rocket Science blog at Discover.

So it won’t be a surprise to learn that Yong wanted more information. He understood that there wasn’t a typical peer-reviewed study published yet, but he wanted to at least speak with the author, whose contact information didn’t seem to be anywhere on the web. So he asked the press officer for those details.

That’s where the ridiculousness started, as Yong relates on his Posterous. The PIO, the University of Manchester’s Aeron Haworth, responded:

Why the New England Journal of Medicine’s handling of a spina bifida study embargo makes me doubt their good intentions

On Friday, I received an email from the Children’s Hospital of Philadelphia, headlined:

Fetal Surgery Takes a Huge Step Forward in Treating Children with Spina Bifida

This finding, according to the release, was being published in the New England Journal of Medicine (NEJM). On the third page, there were some specific data:

The current study reports data on 158 patients who were followed at least one year after surgery. Clinicians who were independent of the surgical teams and blinded (not informed which of the two surgeries a given child received) evaluated the children from the study at one year of age and again at age 30 months.

–At one year of age, 40 percent of the children in the prenatal surgery group had received a shunt, compared to 83 percent of the children in the postnatal group. During pregnancy, all the fetuses in the trial had hindbrain herniation. However, at age 12 months, one-third (36  percent) of the infants in the prenatal surgery group no longer had any evidence of hindbrain herniation, compared to only 4 percent in the postnatal surgery group.

–At age 30 months, children in the prenatal group had significantly better scores in measurements of motor function. While the ability to walk depends on the level of the spina bifida lesion, the study found a twofold increase in the proportion of children able to walk without crutches or other assistive devices—42 percent in the prenatal group compared to 21 percent in the postnatal group.

That all sounded worth looking into. But the release came with a strict embargo:

Please do not share this with anyone as it is still under embargo until 5pm on Wednesday.

There were two strange things about this release.

AMA release fouled by internal glitch the week AP technical glitch breaks JAMA embargo

For the second time in a month, an embargoed — well, sort of — press release has come back to bite an institution in the ass.

Last night, at 5:26 p.m. Eastern, the American Medical Association was forced to send this email, subject line “Note from AMA regarding technical glitch,” to its press list after sending out a release that should have been marked embargoed:

NEJM lifts c difficile embargo early after Montreal Gazette breaks it; Optimer stock spikes

The New England Journal of Medicine (NEJM) lifted the embargo early on a study of a new drug for tough-to-treat intestinal infections today, after a Montreal Gazette story broke the embargo. From an email from the NEJM’s press office at 12:18 Eastern today:

It’s Complicated: The Lancet debuts a new embargo system

Yesterday, The Lancet launched a new embargo system they’re trying for the month of February. In an email that went to the journal’s press list last week, media relations manager Tony Kirby explained that the changes were in response to a survey of 250 journalists last September. The highlights?

AP technical glitch unintentionally breaks JAMA Avastin study embargo

An AP story on a JAMA study about beleaguered cancer drug Avastin broke the 4 p.m. Eastern embargo by several hours today when it appeared on at least one site thanks to a technical glitch.

The story on “Treatment-Related Mortality  With Bevacizumab in Cancer Patients”  showed up on the Taiwan News site sometime before 2 p.m Eastern. JAMA/Archives spokesperson Jann Ingmire tells Embargo Watch: